Succinic Semialdehyde Dehydrogenase Deficiency: An Update. 2020

Miroslava Didiášová, and Antje Banning, and Heiko Brennenstuhl, and Sabine Jung-Klawitter, and Claudio Cinquemani, and Thomas Opladen, and Ritva Tikkanen
Institute of Biochemistry, Medical Faculty, University of Giessen, Friedrichstrasse 24, 35392 Giessen, Germany.

Succinic semialdehyde dehydrogenase deficiency (SSADH-D) is a genetic disorder that results from the aberrant metabolism of the neurotransmitter γ-amino butyric acid (GABA). The disease is caused by impaired activity of the mitochondrial enzyme succinic semialdehyde dehydrogenase. SSADH-D manifests as varying degrees of mental retardation, autism, ataxia, and epileptic seizures, but the clinical picture is highly heterogeneous. So far, there is no approved curative therapy for this disease. In this review, we briefly summarize the molecular genetics of SSADH-D, the past and ongoing clinical trials, and the emerging features of the molecular pathogenesis, including redox imbalance and mitochondrial dysfunction. The main aim of this review is to discuss the potential of further therapy approaches that have so far not been tested in SSADH-D, such as pharmacological chaperones, read-through drugs, and gene therapy. Special attention will also be paid to elucidating the role of patient advocacy organizations in facilitating research and in the communication between researchers and patients.

UI MeSH Term Description Entries
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002658 Developmental Disabilities Disorders in which there is a delay in development based on that expected for a given age level or stage of development. These impairments or disabilities originate before age 18, may be expected to continue indefinitely, and constitute a substantial impairment. Biological and nonbiological factors are involved in these disorders. (From American Psychiatric Glossary, 6th ed) Child Development Deviations,Child Development Disorders,Child Development Disorders, Specific,Developmental Delay Disorders,Disabilities, Developmental,Development Disorders, Child,Child Development Deviation,Child Development Disorder,Development Deviation, Child,Development Deviations, Child,Development Disorder, Child,Developmental Delay Disorder,Developmental Disability,Deviation, Child Development,Disability, Developmental
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D005680 gamma-Aminobutyric Acid The most common inhibitory neurotransmitter in the central nervous system. 4-Aminobutyric Acid,GABA,4-Aminobutanoic Acid,Aminalon,Aminalone,Gammalon,Lithium GABA,gamma-Aminobutyric Acid, Calcium Salt (2:1),gamma-Aminobutyric Acid, Hydrochloride,gamma-Aminobutyric Acid, Monolithium Salt,gamma-Aminobutyric Acid, Monosodium Salt,gamma-Aminobutyric Acid, Zinc Salt (2:1),4 Aminobutanoic Acid,4 Aminobutyric Acid,Acid, Hydrochloride gamma-Aminobutyric,GABA, Lithium,Hydrochloride gamma-Aminobutyric Acid,gamma Aminobutyric Acid,gamma Aminobutyric Acid, Hydrochloride,gamma Aminobutyric Acid, Monolithium Salt,gamma Aminobutyric Acid, Monosodium Salt
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000592 Amino Acid Metabolism, Inborn Errors Disorders affecting amino acid metabolism. The majority of these disorders are inherited and present in the neonatal period with metabolic disturbances (e.g., ACIDOSIS) and neurologic manifestations. They are present at birth, although they may not become symptomatic until later in life. Amino Acidopathies, Congenital,Amino Acid Metabolism Disorders, Inborn,Amino Acid Metabolism, Inborn Error,Amino Acid Metabolism, Inherited Disorders,Amino Acidopathies, Inborn,Congenital Amino Acidopathies,Inborn Errors, Amino Acid Metabolism,Inherited Errors of Amino Acid Metabolism,Amino Acidopathy, Congenital,Amino Acidopathy, Inborn,Congenital Amino Acidopathy,Inborn Amino Acidopathies,Inborn Amino Acidopathy
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

Miroslava Didiášová, and Antje Banning, and Heiko Brennenstuhl, and Sabine Jung-Klawitter, and Claudio Cinquemani, and Thomas Opladen, and Ritva Tikkanen
September 1984, Journal of neurogenetics,
Miroslava Didiášová, and Antje Banning, and Heiko Brennenstuhl, and Sabine Jung-Klawitter, and Claudio Cinquemani, and Thomas Opladen, and Ritva Tikkanen
September 2011, Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics,
Miroslava Didiášová, and Antje Banning, and Heiko Brennenstuhl, and Sabine Jung-Klawitter, and Claudio Cinquemani, and Thomas Opladen, and Ritva Tikkanen
March 2013, Fortschritte der Neurologie-Psychiatrie,
Miroslava Didiášová, and Antje Banning, and Heiko Brennenstuhl, and Sabine Jung-Klawitter, and Claudio Cinquemani, and Thomas Opladen, and Ritva Tikkanen
April 2010, Pediatric neurology,
Miroslava Didiášová, and Antje Banning, and Heiko Brennenstuhl, and Sabine Jung-Klawitter, and Claudio Cinquemani, and Thomas Opladen, and Ritva Tikkanen
September 2003, Zhonghua er ke za zhi = Chinese journal of pediatrics,
Miroslava Didiášová, and Antje Banning, and Heiko Brennenstuhl, and Sabine Jung-Klawitter, and Claudio Cinquemani, and Thomas Opladen, and Ritva Tikkanen
February 2000, Neuropediatrics,
Miroslava Didiášová, and Antje Banning, and Heiko Brennenstuhl, and Sabine Jung-Klawitter, and Claudio Cinquemani, and Thomas Opladen, and Ritva Tikkanen
May 2003, Neurology,
Miroslava Didiášová, and Antje Banning, and Heiko Brennenstuhl, and Sabine Jung-Klawitter, and Claudio Cinquemani, and Thomas Opladen, and Ritva Tikkanen
January 1985, Journal of inherited metabolic disease,
Miroslava Didiášová, and Antje Banning, and Heiko Brennenstuhl, and Sabine Jung-Klawitter, and Claudio Cinquemani, and Thomas Opladen, and Ritva Tikkanen
January 2003, Annals of neurology,
Miroslava Didiášová, and Antje Banning, and Heiko Brennenstuhl, and Sabine Jung-Klawitter, and Claudio Cinquemani, and Thomas Opladen, and Ritva Tikkanen
May 2006, Brain research,
Copied contents to your clipboard!